Home

CARB-X is accelerating global antibacterial innovation by investing in the development of new antibiotics and other life-saving products to combat the most dangerous drug-resistant bacteria. Our projects represent the world’s largest pre-clinical and early development pipeline of antibiotics and other therapeutics, diagnostics, microbiome, vaccines, and devices.

107+

$million

Invested

35

company

Projects

6

different

Countries

13

focused on new classes

Pipeline

The Challenge

Accelerate the development of novel antibiotics and other new approaches to address the emergence of drug-resistant superbugs.
Learn More


Spotlight on Science

SciBac is fighting fire with fire by using improved bugs as drugs

Learn More

“Antibiotics transformed modern medicine but overuse and inappropriate use have led to dangerous bacteria developing deadly resistance. Drug discovery must go hand-in-hand with concerted action to ensure antibiotics of last resort are reserved for patients where first-line treatments will not work. And we must ensure these treatments are available in all countries for those who need them.”

— Tim Jinks, Head of Drug Resistant Infections, Wellcome Trust
Watch this video with Tim Jinks on what Wellcome Trust is doing to address the rise of drug-resistant bacteria.

Funders

ASPR
BARDA
WellcomeTrust
NIAID
UK Government

Alliance Partners

Bill and Melinda Gates Foundation

Accelerators and other partners

Events

Events

03.25.19

Boston, MA

Inaugural Bacteriophage Therapy Summit

03.26.19

Bloomsbury, United Kingdom

The Economist Antimicrobial Resistance Summit - Preventing an Antibiotic Apocalypse

03.28.19

,

Webinar - Clinical development for non-developers Part 3: Antibacterial Drug Enhancer Combinations and Non-traditional Products

CARB-X News

  • 03.14.2019  |  Germany joins CARB-X partnership in the fight against deadly drug-resistant superbugs full release

  • 03.04.2019  |  CARB-X funds ContraFect to develop a new class of antibiotics to treat serious infections caused by Gram-negative ESKAPE superbugs full release

  • 02.25.2019  |  CARB-X expands its Global Accelerator Network to support the development of antibiotics, rapid diagnostics, vaccines and other life-saving products to combat drug-resistant superbugs full release

See All News

In The News

  • 03.19.2019  |  AMR Conference in Berlin: Call for better incentives full story

  • 03.14.2019  |  Germany joins the CARB-X partnership: Invests €39M to incentivise the early development of antibiotics, vaccines, and diagnostics to combat AMR full story

  • 03.14.2019  |  Backgrounder: Why CARB-X is building its accelerator network in Europe? full story

See All News

Sign up for CARB-X news

Get the latest news and announcements from CARB-X.